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Abstract
Aims/hypothesis The aim of this study was to compare the
long-term outcomes—in terms of glucose control, renal func-
tion and procedure-related complications—of simultaneous
islet–kidney (SIK) transplantation with those of simultaneous
pancreas–kidney (SPK) transplantation in patients with type 1
diabetes mellitus.
Methods HbA1c, need for insulin, GFR and complication
rate were compared between 13 recipients of SIK and 25
recipients of SPK transplants at the same institution. The
mean follow-up was 41 months.
Results Two primary organ non-functions occurred in the
SIK group. HbA1c did not differ at any time point during
follow-up in the SIK group compared with the SPK group
(mean during follow-up 6.3 vs 5.9%). Similarly, kidney
function over time was not different between the two groups.
A higher rate of insulin independence following SPK trans-
plantation (after 1 year 96 vs 31% in the SIK group) was
counterbalanced by a higher rate of serious adverse events
(40% relaparotomies vs 0% in the SIK group).
Conclusions/interpretation The endogenous insulin produc-
tion achieved by islet transplantation, combined with optimal
insulin therapy, was sufficient for maintaining near-normal
glucose levels. In terms of glucose control, islet transplan-
tation provides results comparable to those achieved with
pancreas transplantation. However, SPK results in a higher
rate of insulin independence, albeit at the cost of more
surgical complications. These results have led to a new
paradigm in islet transplantation at our institution, where the
primary goal is not insulin independence, but good glucose
control and avoidance of severe hypoglycaemia.
Keywords CGMS(continuousglucosemonitoring system) .
GFR (glomerular filtration rate) . Hypoglycaemia .
Insulin independence . Islet transplantation .
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Abbreviations
CGMS continuous glucose monitoring system
IEQ islet equivalents
KTA kidney transplantation alone
MDRD modification of diet in renal disease
SIK simultaneous islet–kidney transplantation
SPK simultaneous pancreas–kidney transplantation
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Introduction
Transplantation of isolated islets of Langerhans is an
accepted treatment option for patients with type 1 diabetes
mellitus. In 2000, insulin independence was achieved con-
sistently with a steroid-free immunosuppression protocol
[1]. Islet transplantation, therefore, has emerged as an alter-
native to whole-organ pancreas transplantation, a procedure
which has been carried out since 1966 [2], mainly as
simultaneous pancreas–kidney transplantation (SPK) in
patients with type 1 diabetes mellitus and renal failure due
to diabetic nephropathy.
At the University Hospital of Zurich, a tertiary referral
hospital, SPK transplantation has been performed since 1973.
In 2000, the procedure and immunosuppression protocol
were standardised according to results published by Sollinger
et al. [3]. In the same year, the clinical islet transplant
programme was initiated using the Edmonton protocol [4].
Both treatment options have been offered to patients with
type 1 diabetes mellitus and end-stage renal failure. Trans-
plantation of pancreatic beta cells, either as transplantation
of the whole pancreas or of isolated islets, is performed
at our institution exclusively in combination with kidney
transplantation. SPK is an intervention with proven benefits
in terms of survival [5], whereas in pancreas transplantation
alone controversial results have been published [6, 7].
To the best of our knowledge, no data exist that directly
compare the long-term outcome of these two combined trans-
plantation modalities. The outcome in a heterogeneous group
of patients receiving whole-organ pancreas transplantation
(with or without transplantation of a kidney) was compared
with islet transplantation alone during a mean follow-up of
15months [8], with the authors reporting islet transplantation
alone to be safer than whole-organ transplantation, but with
a shorter duration of insulin independence. However, little
is known about differences in long-term outcome between
simultaneous islet–kidney (SIK) and SPK transplantation.
A randomised design for direct comparison is not ethically
justifiable due to the overt differences with regard to the
surgical procedures. For this reason, we considered a retro-
spective analysis of patients who had received either SIK
or SPK to be a valuable alternative for quantification and
comparison of different outcome parameters.
The aim of this study was to compare SIK and SPK with
regard to differences in demographic characteristics and
outcome parameters such as HbA1c, need for exogenous
insulin, renal function and complications.
Methods
Study design Patients who underwent SPK or SIK at the
University Hospital of Zurich between 1 January 2000 and
31 December 2004 were included. Study entry was defined
as date of transplantation. Follow-up ended on 31 December
2005 or earlier if either of the following occurred: death
of a patient or retransplantation of the kidney.
Patient selection Eligibility criteria were: type 1 diabetes
mellitus and end-stage renal failure with need for dialysis
treatment. Patient selection for one of the protocols was
performed after careful evaluation of possible advantages
and disadvantages, with special regard to age and comor-
bidities. Patients considered to be at higher risk of intra-
operative complications were preferentially assigned to the
less invasive procedure of islet transplantation, while younger
and healthier patients were offered both modalities. To sep-
arate the effect of either of the two interventions from the
effect of other transplantation-associated effects, we included
a group of patients with type 1 diabetes who received kidney
transplantation alone (KTA). As KTA is rarely performed
in patients with type 1 diabetes mellitus at our institution,
all KTA recipients with type 1 diabetes between 1996 and
2004 were included.
Organ procurement and surgical procedures Kidneys and
pancreata were obtained from brain-dead multi-organ cadav-
er donors from different hospitals in Switzerland. Written
informed consent was given by the closest relatives. A
negative serum cross-match between donor and recipient
and AB0 compatibility was required. Organs of donors were
preferentially allocated to recipients of a comparable age.
The transplantation of the pancreas was performed
heterotopically into the abdomen. Portal drainage was applied
through venous anastomosis between the pancreas and the
patient’s superior mesenteric vein. The arterial access of the
transplant was connected to the common iliac artery. All
patients received an exocrine enteric drainage.
Preparation and transplantation of the pancreatic islets
were performed as previously described [4]. Transplanted
islets were not cultured before transplantation. Islet volume
is given as islet equivalents (IEQ) [9].
The islet transplantation protocol was submitted to the
ethics committee of the University Hospital Zurich and
written informed consent was obtained from each patient.
The kidney transplantation was performed in the same
way in all patients by heterotopical transplantation of the
graft into the right or left iliac fossa and connection of the
renal vein and artery to the iliac vessels.
Immunosuppression In the SPK group, a regimen with
tacrolimus (Astellas Pharma, Villars-sur-Glâne, Switzerland)
[10] and mycophenolate mofetil (Roche Pharma, Basel,
Switzerland) [11], as well as prednisone (Streuli Pharma,
Uznach, Switzerland) was used. Induction therapy was per-
formed with basiliximab (Novartis Pharma, Basel, Switzer-
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land). Target long-term trough levels for tacrolimus were
8 to 10 μg/l. Mycophenolate mofetil was administered
twice daily in doses of 1 g. Immunosuppression in patients
receiving KTA did not differ from that in SPK recipients
with the exception that there was no induction therapy.
In the SIK group, immunosuppression was carried out
with tacrolimus and sirolimus (Wyeth Pharma, Zug, Switzer-
land), according to the Edmonton protocol [1]. Induction
therapy was performed with daclizumab (Roche Pharma,
Basel, Switzerland). Target long-term trough levels were 7
to 10 μg/l for sirolimus and 3 to 6 μg/l for tacrolimus.
Follow-up During follow-up, pancreas or islet transplant
function was assessed by HbA1c measurement (reference
values in healthy adults 4.8–5.9%) and need for insulin. In
SIK recipients, C-peptide secretion was measured during
a mixed-meal tolerance test [4] at least every year after
transplantation. Because of the high rate of insulin inde-
pendence, C-peptide was not routinely measured after SPK.
However, we did assess islet function by C-peptide and
insulin stimulation during a mixed-meal test in a represen-
tative sample of five patients. In addition, current continuous
glucose monitoring system (CGMS) measurements were
performed in two representative subgroups from the SIK
(n=5) and SPK (n=5) groups for the assessment of blood
glucose control. Renal function was assessed by serum cre-
atinine and GFR estimated by the four-parameter modifi-
cation of diet in renal disease (MDRD) formula [12]. For
follow-up analysis of organ function, organs with primary
non-function, defined as continued need for dialysis or
absence of stimulated C-peptide (C-peptide <0.2 nmol/l [13])
after transplantation, were excluded. All patients were seen
at least every 6 months for evaluation of transplant function
and adverse events. For assessment of cardiovascular risk,
blood pressure, triacylglycerols, total cholesterol and both
HDL-and LDL-cholesterol were measured, in addition to
glycaemic control. All patients were treated according to
current international guidelines. In particular, insulin treat-
ment after transplantation, if necessary, was carried out with
the same regimen and intensity as before transplantation.
Cost analysis A full-cost analysis of pancreas and islet
transplantation was performed between April 2002 and
February 2003 to evaluate the economic impact of the choice
of either of the two treatment options. The cost analysis
included the following: technical costs, nursing care, inter-
disciplinary medical care, medications, and length of hospital
stay (not including pre-transplantation workup, follow-up,
and rehospitalisations due to complications).
Statistical analysis Data are described as means±SD or
relative frequencies. For the analysis of categorical frequency
data, the χ2 and Fisher’s exact probability procedures were
applied. For comparison of continuous variables in two
independent groups, t test and Mann–Whitney test were
used. A value of p<0.05 was considered significant. The
Bonferroni correction was performed to account for
multiple comparisons (p<0.01 was considered significant
in a 5 year follow-up). (Multiple) linear regression was used
for the testing of correlations.
Results
Patient characteristics Altogether 38 patients were included
in the study, 25 of whom received SPK and 13 SIK trans-
plants. The demographic characteristics of the patients are
shown in Table 1.
Sex distribution was equal in both groups. The age of the
patients differed significantly (p=0.0001) between the two
groups, as did the duration of diabetes (p=0.0009) before
transplantation. SIK patients also had a slightly higher BMI
(p=0.03). One of the most important comorbidities influ-
Table 1 Patient demographics of patients with SPK, SIK or KTA transplantation
Characteristic SPK SIK p value
(SPK vs SIK)
KTA p value (KTA
vs SPK/SIK)
n 25 13 – 11 –
Sex, male/female (%) 52/48 46/54 1.00 45/55 1.00
BMI (kg/m2) 22.4±2.1 24.7±3.1 0.03 21.9±4.8 0.60
Age at diagnosis of type 1 diabetes (years) 9.6±3.7 10.9±10.6 0.61 17.9±7.6 0.003
Age at transplantation (years) 39.9±6.0 52.6±9.5 0.0001 49.5±7.6 0.04
Diabetes duration (years) 30.3±7.1 41.7±9.1 0.0009 31.6±8.4 0.53
CHD % 40 62 0.30 18 0.16
Intervention for CHD % 12 46 0.04 18 1.00
Pretransplant dialysis (months) 19.4±14.0 28.5±22.5 0.29 42.8±29.1 0.03
Time on waiting list (months) 12.8±11.5 16.6±16.7 0.49 21.5±14.4 0.07
Values are means±SD or percentages
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encing the selection of the treatment option was CHD.
Comparison of the two groups showed that more patients in
the SIK group had interventions for CHD (p=0.04; Table 1).
No difference was detectable regarding time on waiting list
and time on dialysis before transplantation. The control
group of 11 patients with KTA showed similar character-
istics, but with an older age at diagnosis of type 1 diabetes
(p=0.003) and at transplantation (p=0.04), as well as greater
duration of pretransplant dialysis (p=0.03).
Donor characteristics The kidney donors for SPK patients
were significantly younger than SIK donors (33.8±11.5 vs
48.8±10.1 years, p=0.002). HLA-matches (out of six)
between SPK and SIK recipients (1.8±0.9 vs 2.0±0.9, p=
0.80) and the cold ischaemia time of the kidney (13.8±4.3
vs 12.8±3.0 h, p=0.44) did not differ. The characteristics
of islet donors and islet isolation outcomes are given in
Table 2.
Complications Surgical complications during the first
3 months after the intervention in both groups are summa-
rised with regard to complications related to the kidney
transplantation and to the pancreas or islet transplantation
in Table 3.
The number of patients with surgical complications
assignable to the kidney transplantation was the same in
both groups, as was the number of patients requiring a
revision of the site of kidney transplantation. Most of these
complications were due to postoperative bleeding.
There were only two cases of minor liver bleeding
without need for surgical revision in islet transplanted
patients, whereas in pancreas transplantation 12 patients
(48%) suffered complications. Ten (40%) patients in the
pancreas transplant group underwent relaparotomy for diag-
nostic or therapeutic reasons, which is significantly different
in comparison to the SIK patients (0%; p=0.04). The indi-
cations for relaparotomy were bleeding (two), infection
(two), intestinal obstruction and volvulus (two), ischaemia
(one) and relaparotomy for diagnostic reasons in unclear
cases (three).
Follow-up Mean postoperative follow-up of all patients was
42 months (range 13–66 months) in the SPK and 38 months
(range 12–67) in the SIK group.
There were two primary non-functions in the SIK group,
one patient with primary non-function of the islet transplant
and one patient with primary non-function of the islet and
kidney transplant (retransplanted 2 years after the first trans-
Table 2 Donor characteristics of the SIK group
Patient
number
Tx (n) Donor age
(years)
Donor
weight (kg)
Cold ischaemia
time (h:min)
Total IEQ
per Tx
Total islet number
per Tx
Isolation index (Islet
equivalents/number
of islets)
SIK 1 5 51.2±9.1 72.6±9.9 5:59±2:14 359,473±117,487 227,300±91,698 1.69±0.54
SIK 2 4 51.0±17.4 100.0±47.3 5:48±3:27 317,510±101,640 258,750±204,873 1.64±0.78
SIK 3 3 50.6±12.5 74.7±15.5 5:30±1:13 372,204±144,496 218,333±15,373 1.70±0.66
SIK 4 1 35.7 100.0 4:46 324,644 194,000 1.67
SIK 5 3 41.0±3.4 86.7±12.6 7:11±1:56 414,532±210,351 237,667±135,463 2.22±1.78
SIK 6 2 47.4±14.7 81.9±8.6 5:36±1:25 374,772±193,150 201,500±130,815 1.96±0.32
SIK 7 1 42.1 71.0 2:44 279,703 214,000 1.31
SIK 8 4 56.0±12.7 84.5±11.4 6:51±1:57 402,469±207,688 184,250±32,806 2.14±1.01
SIK 9 1 53.3 57.0 7:23 135,992 245,000 0.56
SIK 10 1 62.1 75.0 9:12 335,336 232,000 1.45
SIK 11 1 51.0 78.0 2:54 375,389 145,000 2.59
SIK 12 1 56.8 70.0 7:08 270,314 366,500 0.74
SIK 13 1 60.3 77.0 12:00 153,564 342,000 0.45
Mean 2.2±1.3 50.5±11.0 81.3±20.08 6:19±2:26 345,070±137,511 229,214±100,214 1.71±0.86
Values given as ± are means±SD
Tx, transplantation
Table 3 Local complications
during the first 3 months after
the intervention in the SPK and
SIK transplantation groups
Values are n (%)
Tx, transplantation
Characteristic SPK SIK p value
Total number of patients in each group 25 13 –
Patients with complications (pancreas/islets) 12 (48) 2 (15) 0.19
Patients with complications (kidney) 5 (20) 3 (23) 1.00
Patients with (re)laparotomy because of the pancreas/islet Tx 10 (40) 0 (0) 0.04
Patients with revision because of the kidney transplantation 2 (8) 2 (15) 0.61
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plantation). The first transplanted kidney in this patient
originated from a 53-year-old marginal organ donor (long
hypotensive episode, pulmonary oedema, resuscitation). The
second kidney of the same organ donor transplanted in a
patient without diabetes also failed to function. There was no
case of primary non-function in the SPK group.
One islet–kidney recipient died 1 year after transplanta-
tion due to cerebral ischaemia not related to transplantation
(confirmed by autopsy).
Glucose control and stimulated C-peptide response HbA1c
values over time are shown in Table 4. The preoperative
values did not differ between the two groups, nor did they
differ significantly during follow-up. Importantly, they
remained stable over time. Similarly, HbA1c before trans-
plantation was not different between KTA recipients and
the two groups with beta cell replacement. In contrast, post-
transplant HbA1c levels of the KTA group were higher than
the pretransplant levels. During the first 3 years after
transplantation HbA1c in patients with KTA was signifi-
cantly different as compared with patients who received
beta cell replacement (SPK or SIK, p<0.01). Thereafter, the
difference persisted, but due to the low number of patients
with a follow-up of longer than 3 years in the SIK group,
the difference was no longer significant.
Stimulated C-peptide concentration 1 year after trans-
plantation in the SIK group was ≥0.2 nmol/l in 11 of 13
patients and in 10 of 13 at the end of follow-up (Table 5). In
Table 4 Preoperative (0 months) and postoperative (12, 24, 36, 48, 60 months) assessment of glucose control (HbA1c) and renal function (GFR
estimated by MDRD) in SPK, SIK and KTA transplantation patients
t Number of patients HbA1c (%) GFR (ml min
−1 1.73 m−2)
SPK SIK KTA SPK SIK p value KTA p value
(KTA vs SIK)
SPK SIK p value KTA p value
(KTA vs SIK)
0 25 13 11 8.7±1.9 8.1±1.5 0.34 8.1±1.1 0.71 10.4±4.1 11.8±6.7 0.81 9.4±2.1 0.48
12 25 13 11 6.0±0.6 6.2±0.8 0.32 9.0±1.9 0.0009 64.7±14.7 53.2±20.2 0.09 54.5±11.1 0.98
24 22 9 10 5.7±0.5 6.3±0.7 0.01 8.5±1.5 0.005 67.5±17.3 51.8±24.5 0.09 53.2±14.9 0.73
36 15 8 9 5.8±0.4 6.7±1.0 0.03 9.1±1.3 0.007 67.3±12.5 49.6±24.0 0.06 47.6±17.9 0.95
48 10 5 9 5.5±0.6 6.2±0.5 0.11 8.8±2.1 0.03 63.5±28.1 49.5±17.2 0.25 46.1±10.0 1.00
60 3 1 9 5.3 5.7 – 8.4±0.7 – 47.9±25.5 53.0 – 48.5±9.2 –
Values are means±SD
Significance was defined as p<0.01 (Bonferroni correction applied)
t, time in months
Table 5 Time points of beta cell replacement in the SIK group, with stimulated C-peptide concentrations and maximally stimulated glucose levels
at different time points after islet transplantation
Patient Time of beta cell
replacement (months)
Follow-up (months) Maximally stimulated C-peptide (nmol/l) Maximally stimulated glucose (mmol/l)
After last Tx 1 year End of follow-up After last Tx 1 year End of follow-up
SIK 1 0, 2, 9, 15, 22 67 3.71 1.36 1.91 7.6 16.1 8.9
SIK 2 0, 0, 26, 39 58 1.64 0.77 0.73 10.1 10.6 10.6
SIK 3 0, 0, 40 57 2.66 2.20 2.14 8.1 7.4 12.7
SIK 5 0, 5, 6 51 1.35 1.78 1.00 10.9 5.8 12.8
SIK 6 0, 11 45 0.68 0.68 0.11 16.4 16.4 17.9
SIK 7 0 40 2.96 0.24 0.21 10.6 11.8 26.7
SIK 8 0, 3, 6, 33 39 1.93 2.09 1.93 10.1 10.8 10.1
SIK 10 0 12a 1.57 1.02 1.02a 9.1 5.2 5.2a
SIK 11 0 21 0.87 1.26 1.26 12.9 14.9 14.9
SIK 12 0 13 0.26 0.20 0.20 14.3 15.5 15.5
SIK 13 0 12 0.24 0.54 0.54 17.6 22.8 22.8
Islet primary non-function (patients SIK 4, SIK 9) has been excluded
a Death of patient before end of follow-up
Tx, transplantation
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the representative sample of SPK patients who underwent a
meal stimulation test, the stimulated C-peptide levels were
significantly higher than in the SIK group at the end of
follow-up (mean 2.505±0.762 in the SPK group vs 1.005±
0.735 nmol/l in the SIK group).
Current CGMS measurements in the representative SPK
and SIK groups (mean 53.6±23.0 and 59.2±24.2 months
after transplantation, respectively) showed less variability
of glucose values, particularly of postprandial levels, in the
SPK group (Fig. 1).
Insulin independence The number of islet transplantations
in the SIK group was 28 (mean: 2.2 per patient; Table 2).
Initial insulin independence was achieved in five of seven
patients who received two ore more islet transplantations,
but persisted only in two of them. In contrast, in the SPK
group all but one patient remained insulin-free. Insulin
independence in all groups 1 year after transplantation was
96 and 31% in SPK and SIK, respectively. The insulin dose
required to achieve near-normal glucose levels in SIK
patients was half of that needed before transplantation, i.e.
0.56±0.17 and 0.29±0.21 U kg−1 day−1 before and after
transplantation (mean dose during follow-up), respectively.
The amount of insulin needed during follow-up was
strongly dependent on the volume of transplanted islets.
When the SIK group was divided into patients who received
less than 10,000 IEQ/kg in total (mean 4,662±2,660 IEQ/kg)
and those treated with more than 10,000 IEQ/kg (mean
23,537±7,363 IEQ/kg), the difference in insulin need
(mean during follow-up) was 0.39±0.14 versus 0.08±
0.06 U kg−1 day−1 (p=0.02). However, HbA1c (mean during
follow-up) was not significantly different between the two
groups (6.2±0.5% in patients with more than 10,000 islets
transplanted and 6.3±0.8% in patients with less than 10,000
islets transplanted, p=0.87; Fig. 2a,b). The mean HbA1c in
the SPK group during follow-up was 5.9±0.5%.
Hypoglycaemia In all patients treated with SPK or SIK trans-
plantation, there were no episodes of severe hypoglycaemia
(grades II and III) after transplantation, even in SIK patients
treated with insulin after transplantation and despite the sig-
nificantly better blood glucose control (i.e. reduction of HbA1c
from 8.4% pre-transplant to 6.3% post-transplant, mean
during follow-up). Before transplantation severe episodes
of hypoglycaemia had occurred in 10 out of 13 SIK patients.
Kidney function The estimated GFR (MDRD) in the three
groups is shown in Table 4. The non-significant differences
Fig. 1 CGMS measurements in a five recipients of SPK transplan-
tation and b five recipients of SIK transplantation at the end of follow-
up. The dashed lines represent the limits of normal glucose fluctuation
in individuals with no diabetes
Fig. 2 a Correlation between mean insulin dose during the whole
follow-up after transplantation and transplanted IEQ per kg recipient
weight in islet recipients. Regression coefficient r=−0.731, p=0.007.
b Correlation between mean HbA1c during the whole follow-up after
transplantation and transplanted IEQ per kilogram recipient weight in
islet recipients. Regression coefficient r=−0.138, p=0.67
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in the estimated GFR between SPK and SIK recipients are
best explained by the difference in donor and recipient age
(Tables 1 and 2). Linear regression showed that the
postoperative GFR was dependent on the age of the kidney
donors (r=−0.54, p=0.0007). There was no difference in
kidney function between patients with beta cell replacement
(SPK, SIK) and those without (KTA).
Cardiovascular risk factors during follow-up Blood pres-
sure, triacylglycerols, total cholesterol and both HDL-and
LDL-cholesterol are shown in Table 6. No significant dif-
ference was observed between the two groups pretransplant
and during the 5 year follow-up period.
Immunosuppression during follow-up Prednisone, given to
SPK recipients, was tapered to 5 mg/day or less in 76% of
patients after 1 year and 91% of patients after 2 years.
Full cost analysis The cost of SPK transplantation in our in-
stitution was 57,772±30,649 € as compared with 53,693±
8,603 € for SIK and 33,805±16,603 € for KTA. The cost
of islet transplantation after SIK was 18,778±302 €. The
hospitalisation times for SPK, SIK and KTA were 22±12,
18±7 and 15±9 days, respectively. Patients with islet trans-
plantation after SIK were discharged within 1 day. The cost
of SIK transplantation on the basis of 2.2 islet transplan-
tations (mean of this study per patient) would thus amount
to 76,227±8,966 €.
Discussion
This is the first direct single centre comparison of SIK and
SPK as treatment for type 1 diabetes mellitus and renal
failure. The aim was to compare the outcome of these two
treatment options performed at the same institution and
followed up by the same team with identical levels of care.
Both transplantation options have become important treat-
ment alternatives to intensive insulin treatment for patients
with type 1 diabetes mellitus. Whole-organ transplantation is
offered mainly to patients with type 1 diabetes and end-stage
renal failure, since pancreas transplantation is reimbursed
by the Swiss health care system only for this indication due
to the better survival of SPK as compared with KTA patients
[14, 15].
Table 6 Preoperative (0 months) and postoperative assessment of clinical characteristics for SPK and SIK patients
Clinical characteristics Time (months)
0 12 24 36 48 60
Systolic BP (mmHg)
SPK 151±23 135±23 144±16 134±11 138±18 136
SIK 146±22 134±18 133±19 137±21 146±23 162
p value 0.70 0.69 0.26 0.96 0.56 –
Diastolic BP (mmHg)
SPK 86±13 78±14 83±11 77±5 80±13 77
SIK 84±13 68±5 78±20 71±12 84±12 82
p value 0.92 0.04 0.66 0.34 0.63 –
Triacylglycerol (mmol/l)
SPK 1.7±0.9 1.3±0.5 1.0±0.4 0.9±0.2 0.9±0.2 0.7
SIK 1.8±1.1 1.5±0.8 1.5±0.4 1.2±0.2 1.6±1.0 0.6
p value 0.69 0.55 0.03 0.03 0.11 –
Total cholesterol (mmol/l)
SPK 4.4±1.2 4.2±1.2 3.9±1.0 4.1±0.9 4.1±0.9 1.6
SIK 5.4±1.4 4.9±0.9 4.8±1.0 4.7±1.0 5.5±1.0 3.2
p value 0.02 0.05 0.08 0.38 0.05 –
HDL-cholesterol (mmol/l)
SPK 1.5±0.5 1.5±0.3 1.5±0.4 1.5±0.5 1.5±0.6 0.5
SIK 1.5±0.6 1.6±0.5 1.5±0.3 1.7±0.6 1.9±0.3 1.6
p value 0.95 0.64 0.76 0.55 0.28 –
LDL-cholesterol (mmol/l)
SPK 2.2±0.9 2.1±1.0 2.1±0.7 2.2±0.7 2.2±0.6 0.8
SIK 3.0±1.1 2.6±0.7 2.6±0.9 2.5±0.6 2.9±1.0 1.3
p value 0.03 0.08 0.20 0.48 0.07 –
Values are means±SD
Significance was defined as p<0.01 (Bonferroni correction applied)
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Some differences between the two procedures are obvious,
e.g. the more invasive character of whole-organ transplanta-
tion compared with the transplantation of isolated islets. A
randomised trial was not feasible due to inherent differences
in the transplantation procedures and associated complica-
tions, which favour whole-organ transplantation in younger
patients with fewer comorbidities. Therefore, we retrospec-
tively analysed the results of beta cell replacement in both
groups. These considerations are reflected by the different
demographic findings in the two groups.
The beneficial effect on glucose control has been indi-
vidually described both for SPK [16] and SIK patients [4].
We were able to demonstrate a significant improvement of
HbA1c values after transplantation in both groups, whereas
in a group of patients who received KTA HbA1c increased
after transplantation, probably due to the immunosuppres-
sive regimen (steroids) in addition to persistent problems in
diabetes management.
Post-transplant HbA1c values in the beta cell replacement
groups were comparable and remained stable during follow-
up. The non-significant difference in HbA1c levels is best
explained by elevated postprandial glucose levels in SIK
patients as seen in the CGMS measurements. Monnier et al.
[17] were able to show that in patients with HbA1c <7.3%,
70% of the HbA1c value is determined by postprandial glu-
cose levels.
However, long-term insulin independence was much
lower in the SIK group, with only two of 13 patients being
insulin-independent at the end of follow-up (48 and
60 months after transplantation), a result which is in line
with the findings of the Edmonton group [18]. A decrease
either in mass or function of islets over time after trans-
plantation occurs for different reasons. Apart from impending
graft rejection, these include the potentially harmful effects
of immunosuppressive drugs at high doses in the portal
circulation [19] or failure of sufficient regeneration.
Nevertheless, the remaining islet mass and function—as
reflected by a positive C-peptide response in eleven out of
13 patients 1 year after transplantation—is sufficient to
maintain glucose control (assessed by HbA1c levels and
CGMS measurements) at a near-normal and significantly
lower level than pretransplantation for several years at the
least. Interestingly, our data show that there was only a
marginal benefit in terms of glucose control in those patients
who received multiple islet transplantations in contrast to
their clear benefit when comparing the amount of exogenous
insulin administered. This finding and the non-significant
difference in glucose control between SIK and SPK patients
despite much higher C-peptide levels and insulin inde-
pendence in the latter group show that the findings of the
DCCT [20, 21] also apply to patients after islet transplan-
tation. Thus even a minor residual beta cell function can sig-
nificantly improve glycaemic control, provided that patients
are intensively treated (continuous subcutaneous insulin
infusion or multiple insulin injections). Given the restricted
availability of donor organs in our institution, we generally
do not repeat islet transplantation to achieve insulin indepen-
dence, unless endogenous insulin secretion is insufficient to
achieve target HbA1c levels. In the present study, this is
reflected by the low number of insulin-independent patients
(31%) 1 year after transplantation in the SIK group compared
with the SPK group. International multicentre data also suggest
that even in islet transplantation alone, insulin independence
after 1 year cannot be achieved in the majority of patients
who undergo transplantation of islets up to three times [22].
One important point in the context of multiple (repetitive)
islet transplantations is the cost. In our setting, costs for SIK
are lower than for SPK by ∼10%, but exceed these if two or
more islet transplantations have to be performed. However,
these numbers do not take follow-up costs due to complica-
tions and/or rehospitalisation into account.
Life-long immunosuppression, which is required for the
kidney transplant, is not an additional cost factor or risk fac-
tor for major complication in SIK transplantation. The costs
of islet transplantation are justified by amuch better glycaemic
control (without hypoglycaemia) than that achieved in
intensive insulin trials [23] or in our control group with KTA.
In contrast to transplantation of isolated islets, transplan-
tation of the whole organ always aims to achieve insulin
independence, which can, as demonstrated here, be accom-
plished in most patients. The price of this benefit, however,
is a much more invasive procedure with frequent local com-
plications related to the pancreas transplantation. During the
first 3 months after transplantation, 40% of the transplanted
patients had to undergo relaparotomy due to local abdominal
complications related to the operation. Results published by
the European Trial of Immunosuppression in Simultaneous
Pancreas Kidney Transplantation (EUROSPK) study group
show that repeat laparotomies in the first 3 months after
transplantation were performed in 35% of all patients [24].
Large single centre trials show smaller numbers of com-
plications, with the Minnesota group, for example, reporting
relaparotomy in just 19% of patients [25]. Compared with a
large pancreas transplant centre, our centre is rather small.
However, in contrast to these centres, our transplantation
programme processed the same number of pancreata for
pancreas and islet transplantation, allowing a direct compar-
ison of the two methods with no inherent bias. Furthermore,
we sought to prevent loss of function of the transplanted
organ in every possible way, which led to more therapeutic
and diagnostic relaparotomies, resulting in a high pancreas
transplant graft survival of 96% at 1 year, compared with
85% in US pancreas transplants reported to the International
Pancreas Transplant Registry [26].
The most common causes of relaparotomies in the SPK
group were haemorrhage, intestinal obstruction and infec-
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tion. Except for two cases of minor liver bleeding without
need for revision or transfusion, there were no local com-
plications related to islet transplantation in the SIK group.
Complications and surgical revisions due to the kidney
transplantation were comparable in both groups, which
suggests that the two groups had similar susceptibility to
local complications in general.
Renal function of the transplanted kidney does not seem
to be influenced by the choice of one of the two transplan-
tation or immunosuppression options. We were not able to
detect a significant difference in renal function between the
two groups. The tendency towards a better GFR of the
transplanted kidney in the SPK group can be attributed to
the significantly lower recipient and donor ages in this group.
Despite a much higher insulin independence rate and
younger age in the SPK group, the post-transplant cardio-
vascular risk profile (blood pressure, lipid profile and glycated
haemoglobin) was not significantly different between the
two transplant groups.
Immunosuppression was different in the two groups.
Whereas in the SIK group, immunosuppression was carried
out according to the Edmonton protocol using sirolimus
and low-dose tacrolimus, and by strictly avoiding steroids,
the SPK group received a combination therapy of tacrolimus,
mycophenolate mofetil and (initially) steroids. In solitary
kidney transplantations, the latter regimen seems to have
advantages compared with the sirolimus–tacrolimus combi-
nation in terms of graft function and graft survival [27, 28].
However, this was not observed in our series, since kidney
function over time proved to be very stable. With regard to
glucose control, a prospective study did not reveal any
different effects of mycophenolate mofetil and sirolimus in
SPK recipients [29].
A limitation of this study is its retrospective and non-
randomised character and the relatively low number of
patients involved. The major advantage, however, is that
both patient groups were operated at the same institution
and follow-up was performed by the same team. The
collection of follow-up data has a high level of completeness
(HbA1c levels obtained in 87.6%, insulin dosage in 98.2%,
creatinine levels in 100% of cases).
In summary, this study demonstrates that SPK transplan-
tation results in a much higher insulin independence at the
cost of more surgical complications as compared with SIK
transplantation, with glycaemic control comparable in both
groups. Endogenous insulin production by transplanted
islets combined with optimal insulin therapy seems to be
sufficient for maintenance of near-normal glucose levels
and disappearance of severe hypoglycaemia, which we con-
sider to be the primary objectives of islet transplantation.
Particularly in the face of organ shortage, these findings may
lead to a new paradigm in islet transplantation, where the
primary goal is not necessarily to achieve the same rate of
insulin independence as in whole-organ transplantation, but
to achieve a significant improvement in glucose control
through a much less invasive procedure.
Acknowledgements Wegratefully acknowledge theHans-PaulWälchli
Foundation for providing the funding for this study. We thank H. Seiler
and M.-T. Achermann (Department of Endocrinology and Diabetes,
University Hospital Zurich) for superb assistance.
Duality of interest The authors declare that there is no duality of
interest associated with this manuscript.
References
1. Shapiro AM, Lakey JR, Ryan EA et al (2000) Islet transplantation in
seven patients with type 1 diabetes mellitus using a glucocorticoid-
free immunosuppressive regimen. N Engl J Med 343:230–238
2. Kelly WD, Lillehei RC, Merkel FK, Idezuki Y, Goetz FC (1967)
Allotransplantation of the pancreas and duodenum along with the
kidney in diabetic nephropathy. Surgery 61:827–837
3. Sollinger HW, Odorico JS, Knechtle SJ, D’Alessandro AM,
Kalayoglu M, Pirsch JD (1998) Experience with 500 simultaneous
pancreas–kidney transplants. Ann Surg 228:284–296
4. Lehmann R, Weber M, Berthold P et al (2004) Successful
simultaneous islet–kidney transplantation using a steroid-free immu-
nosuppression: two-year follow-up. Am J Transplant 4:1117–1123
5. Ojo AO, Meier-Kriesche HU, Hanson JA et al (2001) The impact
of simultaneous pancreas–kidney transplantation on long-term
patient survival. Transplantation 71:82–90
6. Gruessner RW, Sutherland DE, Gruessner AC (2004) Mortality
assessment for pancreas transplants. Am J Transplant 4:2018–2026
7. Venstrom JM, McBride MA, Rother KI, Hirshberg B, Orchard TJ,
Harlan DM (2003) Survival after pancreas transplantation in
patients with diabetes and preserved kidney function. JAMA
290:2817–2823
8. Frank A, Deng S, Huang X et al (2004) Transplantation for type I
diabetes: comparison of vascularized whole-organ pancreas with
isolated pancreatic islets. Ann Surg 240:631–640
9. Ricordi C, Gray DW, Hering BJ et al (1990) Islet isolation
assessment in man and large animals. Acta Diabetol Lat 27:185–195
10. Land W, Malaise J, Sandberg J, Langrehr J (2002) Tacrolimus
versus cyclosporine in primary simultaneous pancreas–kidney
transplantation: preliminary results at 1 year of a large multicenter
trial. Transplant Proc 34:1911–1912
11. Merion RM, Henry ML, Melzer JS, Sollinger HW, Sutherland DE,
Taylor RJ (2000) Randomized, prospective trial of mycophenolate
mofetil versus azathioprine for prevention of acute renal allograft
rejection after simultaneous kidney–pancreas transplantation.
Transplantation 70:105–111
12. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D
(1999) A more accurate method to estimate glomerular filtration
rate from serum creatinine: a new prediction equation. Modification
of Diet in Renal Disease Study Group. Ann Intern Med 130:
461–470
13. Palmer JP, Fleming GA, Greenbaum CJ et al (2004) C-peptide is
the appropriate outcome measure for type 1 diabetes clinical trials
to preserve beta-cell function: report of an ADAworkshop, 21–22
October 2001. Diabetes 53:250–264
14. Reddy KS, Stablein D, Taranto S et al (2003) Long-term survival
following simultaneous kidney–pancreas transplantation versus
kidney transplantation alone in patients with type 1 diabetes
mellitus and renal failure. Am J Kidney Dis 41:464–470
118 Diabetologia (2008) 51:110–119
15. Smets YF, Westendorp RG, van der Pijl JW et al (1999) Effect of
simultaneous pancreas–kidney transplantation on mortality of
patients with type-1 diabetes mellitus and end-stage renal failure.
Lancet 353:1915–1919
16. Katz H, Homan M, Velosa J, Robertson P, Rizza R (1991) Effects
of pancreas transplantation on postprandial glucose metabolism.
N Engl J Med 325:1278–1283
17. Monnier L, Lapinski H, Colette C (2003) Contributions of fasting
and postprandial plasma glucose increments to the overall diurnal
hyperglycemia of type 2 diabetic patients: variations with increas-
ing levels of HbA1c. Diabetes Care 26:881–885
18. Ryan EA, Paty BW, Senior PA et al (2005) Five-year follow-up
after clinical islet transplantation. Diabetes 54:2060–2069
19. Desai NM, Goss JA, Deng S et al (2003) Elevated portal vein
drug levels of sirolimus and tacrolimus in islet transplant recipients:
local immunosuppression or islet toxicity? Transplantation 76:
1623–1625
20. The DCCT research group (1987) Effects of age, duration and
treatment of insulin-dependent diabetes mellitus on residual beta-
cell function: observations during eligibility testing for the Diabetes
Control and Complications Trial (DCCT). J Clin Endocrinol Metab
65:30–36
21. Steffes MW, Sibley S, Jackson M, Thomas W (2003) Beta-cell
function and the development of diabetes-related complications in
the diabetes control and complications trial. Diabetes Care 26:
832–836
22. Shapiro AM, Ricordi C, Hering BJ et al (2006) International trial
of the Edmonton protocol for islet transplantation. N Engl J Med
355:1318–1330
23. The DCCT Research Group (1993) The effect of intensive
treatment of diabetes on the development and progression of
long-term complications in insulin-dependent diabetes mellitus.
N Engl J Med 329:977–986
24. Steurer W, Malaise J, Mark W, Koenigsrainer A, Margreiter R
(2005) Spectrum of surgical complications after simultaneous
pancreas–kidney transplantation in a prospectively randomized
study of two immunosuppressive protocols. Nephrol Dial Trans-
plant 20(Suppl 2):ii54–ii62
25. Humar A, Kandaswamy R, Granger D, Gruessner RW, Gruessner
AC, Sutherland DE (2000) Decreased surgical risks of pancreas
transplantation in the modern era. Ann Surg 231:269–275
26. Gruessner AC, Sutherland DE (2005) Pancreas transplant outcomes
for United States (US) and non-US cases as reported to the United
Network for Organ Sharing (UNOS) and the International Pancreas
Transplant Registry (IPTR) as of June 2004. Clin Transplant
19:433–455
27. Ciancio G, Burke GW, Gaynor JJ et al (2006) A randomized long-
term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate
versus cyclosporine/sirolimus in renal transplantation: three-year
analysis. Transplantation 81:845–852
28. Meier-Kriesche HU, Schold JD, Srinivas TR, Howard RJ, Fujita S,
Kaplan B (2005) Sirolimus in combination with tacrolimus is asso-
ciated with worse renal allograft survival compared to mycophenolate
mofetil combined with tacrolimus. Am J Transplant 5:2273–2280
29. Havrdova T, Saudek F, Boucek P et al (2006) Metabolic effect of
sirolimus versus mycophenolate mofetil on pancreatic graft function-
a prospective randomised study. Diabetologia 49(Suppl 1):150–151
(abstract)
Diabetologia (2008) 51:110–119 119
